WPD Pharmaceuticals Inc. signed a contract with Clinigen Clinical Supplies Management to provide critical services during the Berubicin phase 2 adult and phase 1 pediatric clinical trials which are scheduled to start in February 2021 and May 2021, respectively. For nearly half a century, Clinigen has built a reputation as one of the most trusted specialty logistics company in the world through its unsurpassed knowledge, global reach and flawless supply chain execution. Clinigen's global supply chain facility and depot network combines market-leading clinical trial services such as comparator sourcing, packaging and labelling with biological sample management. Clinigen delivers tailored solutions for clients globally to ensure clinical trials are a success, regardless of size or scope, from Phase I to Phase IV Trials. For WPD's trials, Clinigen will cover Qualified Person services for ensuring and confirming that the Berubicin clinical product has been manufactured in accordance to the European Union Good Manufacturing Practice standards. Clinigen will also be responsible for packaging and labeling of the Investigational Medicinal Product, storage in accordance with the product specification and release of the IMP to clinical sites in accordance to Good Distribution Practice. QP certification of the IMP is crucial to obtain approval of the Regulatory Authority and to initiate the clinical trials. WPD aims to conduct the clinical trials with the highest quality and in compliance with the applicable EU regulations and all applicable requirements including GMP. The services provided by Clinigen are expected to last up to 3 years.